Sector News

Johnson Matthey signs supply agreement with US biopharmaceutical firm

September 8, 2020
Chemical Value Chain

Johnson Matthey (JM; London, UK) says it has entered into a five-year supply agreement with Sarepta Therapeutics (Andover, Massachusetts), a biopharmaceutical company.

According to the terms of the agreement, JM will continue to provide regulatory starting materials to support Sarepta’s programs for phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO), used for the treatment of Duchenne muscular dystrophy, the company says.

JM’s innovator products and solutions business that provides custom development and manufacturing (CDMO) services will produce these synthetic regulatory starting materials at its facilities at West Deptford, New Jersey, and Devens, Massachusetts, using their commercial-scale production trains, the company says.

The new agreement strengthens the relationship between the two companies. “Our collaboration with Sarepta signifies our continued commitment to existing and future PPMO and PMO programs, and Sarepta’s mission of engineering precision medicine for rare, devastating diseases,” says Alex Zahiri, vice president/innovator products and solutions, CDMO business at JM.

By: Sotirios Frantzanas

Source: Chemical Week

comments closed

Related News

May 21, 2022

Sika opens new manufacturing plant in Bolivia 

Chemical Value Chain

Sika AG (Baar, Switzerland) has opened a new plant in Santa Cruz de la Sierra, thus doubling its production capacity for mortar and concrete admixtures in Bolivia. With this new facility in one of the country’s main industrial agglomerations, Sika is positioning itself for continued growth in the dynamic Bolivian construction market.

May 21, 2022

Chevron increases renewable fuel market share with REG acquisition

Chemical Value Chain

Chevron Corporation (NYSE: CVX) and Renewable Energy Group, Inc. (NASDAQ: REGI) (REG) announced on Monday a definitive agreement under which Chevron will acquire the outstanding shares of REG in an all-cash transaction valued at $3.15 billion, or $61.50 per share.

May 21, 2022

Lotte Chemical to invest $8 bn on hydrogen energy, battery materials by 2030

Chemical Value Chain

Lotte Chemical Corp. will invest 10 trillion won ($8 billion) on hydrogen and battery materials through 2030 to achieve annual revenue of 50 trillion won and carbon neutrality. The Korean chemical producer on Thursday unveiled its new corporate vision outlining key corporate strategies with focus on growth through hydrogen energy and battery materials businesses.